...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Win or lose....one thing we know for sure

Timely article from John Carroll on Novartis relying on subgroup data for FDA approval of canakinumab and Entresto.

https://endpts.com/once-again-novartis-cardio-team-looks-to-beat-the-odds-using-sketchy-data-and-a-familiar-argument/

 

Share
New Message
Please login to post a reply